FSD Pharma announces Phase II trial for potential COVID-19 treatment 08-Sep-2020 By Jenni Spinner The company has submitted an investigational new drug application for FSD201, a possible therapy for patients with severe cases of the virus.
COVID-19 treatment study predicts adverse drug events 03-Sep-2020 By Jenni Spinner Innovative research by Tabula Rasa Healthcare uses simulation technology to analyze potential adverse drug events of potential therapies for the virus.
COVID-19 report shares insights on potential therapies 01-Sep-2020 By Jenni Spinner A new scientific report offers a comprehensive review of protein targets, associated COVID-19 drug candidates to date and other revealing information.
NIAID awards $44m contract to advance COVID-19 drug 31-Aug-2020 By Jenni Spinner The US institute has given a new contract to drug developer BioCryst to explore use of galidesivir in treatment of non-hospitalized COVID-19 patients.
Front-line physicians offer COVID-19 insights 31-Aug-2020 By Jenni Spinner A recent study from healthcare insights company Sermo shares information and perspectives that trial and pharma professionals could learn from.
SubjectWell eyes diversity in COVID-19 vaccine trials 27-Aug-2020 By Jenni Spinner The clinical trials marketplace company reportedly is connecting sites with 10,000 patients a month, with 40% of them from non-white groups.
